AI assistant
Sending…
Black Diamond Therapeutics, Inc. — Director's Dealing 2021
Feb 19, 2021
33652_dirs_2021-02-19_a8b8a287-f450-4859-89ef-dbba2064d740.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Black Diamond Therapeutics, Inc. (BDTX)
CIK: 0001701541
Period of Report: 2021-02-17
Reporting Person: HUMPHREY RACHEL (Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-17 | Stock Option (Right to Buy) | $28.69 | A | 60000 | Acquired | 2031-02-16 | Common Stock (60000) | Direct |
Footnotes
F1: 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter.
More from Black Diamond Therapeutics, Inc.
Regulatory Filings
2026
May 21
Interim / Quarterly Report
2026
May 7
Earnings Release
2026
May 7
Annual Report
2026
Apr 29
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20
Major Shareholding Notification
2026
Feb 17
Director's Dealing
2026
Jan 23
Director's Dealing
2026
Jan 23
Director's Dealing
2026
Jan 23